title: Aptamers as reagents for high-throughput screening.
abstract: The identification of new drug candidates from chemical libraries is a major component of discovery research in many pharmaceutical companies. Given the large size of many conventional and combinatorial libraries and the rapid increase in the number of possible therapeutic targets, the speed with which efficient high-throughput screening (HTS) assays can be developed can be a rate-limiting step in the discovery process. We show here that aptamers, nucleic acids that bind other molecules with high affinity, can be used as versatile reagents in competition binding HTS assays to identify and optimize small-molecule ligands to protein targets. To illustrate this application, we have used labeled aptamers to platelet-derived growth factor B-chain and wheat germ agglutinin to screen two sets of potential small-molecule ligands. In both cases, binding affinities of all ligands tested (small molecules and aptamers) were strongly correlated with their inhibitory potencies in functional assays. The major advantages of using aptamers in HTS assays are speed of aptamer identification, high affinity of aptamers for protein targets, relatively large aptamer-protein interaction surfaces, and compatibility with various labeling/detection strategies. Aptamers may be particularly useful in HTS assays with protein targets that have no known binding partners such as orphan receptors. Since aptamers that bind to proteins are often specific and potent antagonists of protein function, the use of aptamers for target validation can be coupled with their subsequent use in HTS.
authors.affiliation: NeXstar Pharmaceuticals/Gilead Sciences, Boulder, CO, USA.
authors.forename: L S
authors.initials: LS
authors.lastname: Green
authors.forename: C
authors.initials: C
authors.lastname: Bell
authors.forename: N
authors.initials: N
authors.lastname: Janjic
mesh_terms: D000818:Animals; D000838:Anions; D000077214:Becaplermin; D001667:Binding, Competitive; D004353:Drug Evaluation, Preclinical; D006384:Hemagglutination; D006801:Humans; D007202:Indicators and Reagents; D009130:Muscle, Smooth / Q000378:metabolism; D009696:Nucleic Acids; D009844:Oligosaccharides / Q000378:metabolism; D010761:Phosphorus Radioisotopes; D010982:Platelet-Derived Growth Factor / Q000378:metabolism / Q000494:pharmacology; D020574:Proto-Oncogene Proteins c-sis; D051381:Rats; D017479:Receptors, Platelet-Derived Growth Factor / Q000187:drug effects / Q000378:metabolism; D011994:Recombinant Proteins / Q000378:metabolism / Q000494:pharmacology; D012756:Sheep / Q000097:blood; D013678:Technology, Pharmaceutical; D013936:Thymidine / Q000378:metabolism; D014909:Wheat Germ Agglutinins / Q000378:metabolism / Q000494:pharmacology
chemical_list: D000838:Anions; D007202:Indicators and Reagents; D009696:Nucleic Acids; D009844:Oligosaccharides; D010761:Phosphorus Radioisotopes; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D011994:Recombinant Proteins; D014909:Wheat Germ Agglutinins; D000077214:Becaplermin; D017479:Receptors, Platelet-Derived Growth Factor; D013936:Thymidine